Description du projet
Faire évoluer les protocoles des biobanques
Les études scientifiques reposent souvent sur des échantillons de patients pour valider les résultats précliniques et fournir des informations précieuses sur l’émergence et la progression des maladies. De même, la découverte de biomarqueurs de maladies nécessite des échantillons de patients généralement stockés dans des référentiels biologiques qu’on appelle biobanques. Le traitement des échantillons biologiques reste toutefois un travail laborieux qui nécessite un personnel spécialisé. Le projet ARTS, soutenu par le CER, entend remédier à cette situation grâce à une technologie automatisée basée sur la réalité augmentée, conviviale et généralisable à tous les hôpitaux. Cette plateforme, capable de surveiller le traitement des échantillons, sera plus durable, plus rentable et fournira des tissus de haute qualité à des fins de recherche.
Objectif
Large scale biobanks are essential to meet the world-wide demand for high quality tissues to understand the development and progression of disease, or discover and validate novel biomarkers. Current biobanking protocols for harvesting and processing tissue are manual and therefore rely on experienced and costly on-site personnel. Imagine the possibilities of scientific discoveries in personalized diagnostics, prognostics and treatment if high-quality tissues could be made available from several hospitals using streamlined, harmonized and automated biobanking protocols, that would also allow for maximal utilization of this precious material. In this PoC, we propose a shift from a human centered to a semi- or fully automated tissue harvesting and processing protocol. Specifically, we propose to develop further, test and validate (from TRL4 to TRL7) an Augmented Reality enhanced and automated Tissue Sampler (ARTS), a technology that is cost-effective, simple to operate, and allows for maximal tissue utilization. The ARTS prototype was developed within my ongoing ERC StG and already enables sub-samples to be selected from tissue based on invisible features such as diseased and non-diseased cells – one of the general challenges of biobanking today. In this PoC, we will include comprehensive process monitoring and sample tracking features such as position, temperature and processing time to allow automated sub-sampling while ensuring operator quality assurance with minimal hands-on time. We will also incorporate a tested user-friendly interface ready for industry and a potential spin-off company. ARTS will allow biobanks to serve customers with specific and high-quality targeted sub-samples which will enhance the value of the material through increased reproducibility, faster processing and more efficient utilization. In addition, ARTS will relieve financial burden and achieve more long-term sustainability for biobanks, which typically depend on public funding.
Champ scientifique
Mots‑clés
Programme(s)
- HORIZON.1.1 - European Research Council (ERC) Main Programme
Régime de financement
HORIZON-ERC-POC - HORIZON ERC Proof of Concept GrantsInstitution d’accueil
7491 Trondheim
Norvège